← All trials
NCT04313868
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 13, 2014
- Primary completion
- Oct 7, 2020
- Completion date
- Feb 4, 2021
- First posted
- Mar 18, 2020
- Last posted
- Mar 18, 2020
- Enrollment
- 122
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- GenVivo, Inc.Lead sponsor
- National Kidney and Transplant Institute, PhilippinesOverall official - principal investigator
- Makati Medical CenterOverall official - principal investigator
- Manila Doctors HospitalOverall official - principal investigator
- St. Luke's Medical Center, PhilippinesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.